Realizing the Long-Term Vision “HOPE100”
First written in FY2017-Q1. 23 of 25 entries say "Restated". Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024RestatedAnnual report
「To embody this vision, we formulated the long-term vision, “Vision 110,” looking ahead to the 110th anniversary of our founding in 10 years. We aim to become a company that places its innovative pharmaceuticals business at the core, continuously provides high-value new drugs that address medical needs, develops a broad portfolio of health-related businesses, and makes a wide-ranging contribution to people’s health.」
Vision 110 was reaffirmed as the long-term vision toward the 110th anniversary of the Company’s founding, with the innovative pharmaceuticals business at the core and a broad portfolio of health-related businesses. - FY2024-Q3RestatedAnnual report
「In the fiscal year marking the Group’s 100th anniversary, we launched the newly formulated long-term vision, “Vision 110 (FY2023–FY2032),” and medium-term management plan, “Vision 110—Stage 1—(FY2023–FY2025).”」
Vision 110 and Stage 1 continue as plans covering FY2023–FY2032 and FY2023–FY2025, respectively. - FY2024-Q2RestatedAnnual report
「In the fiscal year marking the Group’s 100th anniversary, we launched the newly formulated long-term vision, “Vision 110 (FY2023–FY2032),” and medium-term management plan, “Vision 110—Stage 1—(FY2023–FY2025).”」
Vision 110 and Stage 1 continue as plans covering FY2023–FY2032 and FY2023–FY2025, respectively. - FY2023ReframedAnnual report
「To embody this vision, we formulated a new long-term vision, “Vision 110 (FY2023–FY2032),” and aim to become a company that places its innovative pharmaceuticals business at the core, continuously provides high-value new drugs that address medical needs, develops a broad portfolio of health-related businesses, and makes a wide-ranging contribution to people’s health.」
Vision 110 replaced HOPE100 as the new long-term vision toward the 110th anniversary of the Company’s founding, with the innovative pharmaceuticals business at its core. - FY2023-Q1RestatedAnnual report
「Against this backdrop, the Group operates under the medium-term management plan, “HOPE100—Stage 3—(FY2020–FY2023),” launched in the fiscal year ending March 2021, with the aim of realizing the long-term vision, “HOPE100.”」
The Group continues to pursue HOPE100 under Stage 3, covering FY2020 through FY2023. - FY2022-Q3RestatedAnnual report
「Against this backdrop, the Group operates under the medium-term management plan, “HOPE100—Stage 3—(FY2020–FY2023),” launched in the fiscal year ending March 2021, with the aim of realizing the long-term vision, “HOPE100.”」
The Group continues to pursue HOPE100 under Stage 3, covering FY2020 through FY2023. - FY2022-Q2RestatedAnnual report
「With the aim of realizing the long-term vision, “HOPE100,” the Group operates under the medium-term management plan, “HOPE100—Stage 3—(FY2020–FY2023),” launched in the fiscal year ending March 2021.」
The Group continues to pursue HOPE100 under Stage 3, covering FY2020 through FY2023. - FY2022-Q1RestatedAnnual report
「With the aim of realizing the long-term vision, “HOPE100,” the Group operates under the medium-term management plan, “HOPE100—Stage 3—(FY2020–FY2023),” launched in the fiscal year ending March 2021.」
The Group continues to pursue HOPE100 under Stage 3. - FY2021-Q3RestatedAnnual report
「Against this backdrop, the Group operates under the new medium-term management plan, “HOPE100—Stage 3—(FY2020–FY2023),” launched this fiscal year, with the aim of realizing the long-term vision, “HOPE100 (through FY2023).”」
HOPE100 continues to be positioned as the long-term vision through FY2023 and the overarching policy of Stage 3. - FY2021-Q2RestatedAnnual report
「Against this backdrop, the Group launched the new medium-term management plan, “HOPE100—Stage 3—(FY2020–FY2023),” this fiscal year with the aim of realizing the long-term vision, “HOPE100.”」
The Group continues to pursue Stage 3, covering FY2020 through FY2023, under HOPE100. - FY2021-Q1RestatedAnnual report
「With the aim of realizing the long-term vision, “HOPE100,” the Group launched the new medium-term management plan, “HOPE100—Stage 3—(FY2020–FY2023),” this fiscal year.」
The Group reaffirmed its aim of realizing HOPE100 under Stage 3, covering FY2020 through FY2023. - FY2020RestatedAnnual report
「Under the long-term vision, “HOPE100,” we aim to evolve into a company that supports healthy living by combining our prescription pharmaceuticals and healthcare businesses, diversifying business risks, and achieving sound, sustainable growth from the perspective of enhancing corporate value over the medium to long term.」
The Group continues to position HOPE100 as the overarching vision and aims for sustainable growth through the combination of its prescription pharmaceuticals and healthcare businesses. - FY2020-Q3RestatedAnnual report
「This fiscal year is the final year of the medium-term management plan, “HOPE100—Stage 2—(FY2016–FY2019),” formulated to realize the long-term vision, “HOPE100 (through FY2023).”」
HOPE100 continues to be positioned as the long-term vision through FY2023 and the overarching policy of Stage 2. - FY2020-Q1RestatedAnnual report
「The medium-term management plan, “HOPE100—Stage 2—(FY2016–FY2019),” was formulated to realize the long-term vision, “HOPE100 (through FY2023).”」
HOPE100 continues to be positioned as the long-term vision through FY2023 and the overarching policy of the medium-term management plan. - FY2019RestatedAnnual report
「With the aim of embodying the corporate philosophy, “KYORIN is committed to cherishing life and fulfilling its social mission of contributing to people’s health,” the Group operates under the long-term vision, “HOPE100 (through FY2023).”」
HOPE100 continues to be positioned as the long-term vision through FY2023 and the overarching policy for embodying the corporate philosophy and enhancing corporate value. - FY2019-Q3RestatedAnnual report
「With the aim of realizing the long-term vision, “HOPE100 (through FY2023),” the Group operates under the medium-term management plan, “HOPE100—Stage 2—(FY2016–FY2019).”」
HOPE100 continues to be positioned as the long-term vision through FY2023 and the overarching policy of Stage 2. - FY2019-Q2RestatedAnnual report
「With the aim of realizing the long-term vision, “HOPE100 (through FY2023),” the Group operates under the medium-term management plan, “HOPE100—Stage 2—(FY2016–FY2019),” which began in FY2016.」
HOPE100 continues to be positioned as the long-term vision through FY2023 and the overarching policy of Stage 2. - FY2019-Q1RestatedAnnual report
「With the aim of realizing the long-term vision, “HOPE100 (through FY2023),” the Group operates under the medium-term management plan, “HOPE100—Stage 2—(FY2016–FY2019),” which began in FY2016.」
HOPE100 continues to be positioned as the long-term vision through FY2023 and the overarching policy of the medium-term management plan. - FY2018RestatedAnnual report
「With the aim of embodying the corporate philosophy, “KYORIN is committed to cherishing life and fulfilling its social mission of contributing to people’s health,” the Group operates under its long-term vision, “HOPE100.”」
HOPE100 was reaffirmed as the overarching policy for embodying the corporate philosophy and enhancing corporate value over the medium to long term. - FY2018-Q3RestatedAnnual report
「Against this backdrop, the Group is operating under the medium-term management plan, “HOPE100—Stage 2—(FY2016–FY2019),” which began in FY2016, with the aim of realizing the long-term vision, “HOPE100.”」
HOPE100 continues to be presented as the overarching vision. - FY2018-Q2RestatedAnnual report
「With the aim of realizing the long-term vision, “HOPE100,” under the medium-term management plan, “HOPE100—Stage 2—(FY2016–FY2019),” which began in FY2016.」
HOPE100 continues to serve as the overarching policy. - FY2017RestatedAnnual report
「In 2010, the Group formulated its long-term vision, “HOPE100,” looking ahead to 2023, the 100th anniversary of the founding of its core subsidiary, KYORIN Pharmaceutical Co.,Ltd.」
HOPE100 was reaffirmed as the long-term vision looking ahead to 2023. - FY2017-Q3RestatedAnnual report
「With the aim of realizing the Group’s long-term vision, “HOPE100,” under the new medium-term management plan, “HOPE100—Stage 2—(FY2016–FY2019),” which began this fiscal year (FY2016).」
The long-term vision continues to serve as the overarching policy of the medium-term management plan. - FY2017-Q2RestatedAnnual report
「With the aim of realizing the long-term vision, “HOPE100,” under the new medium-term management plan, “HOPE100—Stage 2—(FY2016–FY2019),” which began this fiscal year (FY2016).」
The long-term vision continues to serve as the overarching policy. - FY2017-Q1First statedAnnual report
「With the aim of realizing the Group’s long-term vision, “HOPE100,” under the new medium-term management plan, “HOPE100—Stage 2—(FY2016–FY2019),” which began this fiscal year (FY2016).」
The long-term vision is presented as the overarching policy of the medium-term management plan.